Novo Nordisk is proceeding with a multi-million dollar investment in its 170,000-square foot manufacturing facility in West Lebanon, New Hampshire.

The site was acquired by Novo Nordisk in 2014 from Olympus Biotech. Novo Nordisk plans to have a workforce of 150 people by the end of 2016

The facility will produce medicines for the treatment of hemophilia, including the long-acting recombinant factor VIII, N8-GP for those with hemophilia A. The company also recently made the decision to expand its ability to manufacture human growth hormone.

Source: Novo Nordisk